other:Article Title: Tumor-Intrinsic Response to IFNγ Shapes the Tumor Microenvironment and Anti-PD-1 Response in NSCLC
Article Snippet: Antibodies and Reagents: 89Y-CD45, Fluidigm, Clone 30-F11; 141Pr-Gr1 (Ly6C/Ly6G), Fluidigm, Clone RB6-8C5; 142Nd-CD11c, Fluidigm, Clone N418; 143Nd-GITR, Fluidigm, Clone DTA1; 144Nd-MHC class I, Fluidigm, Clone 28-14-8; 145Nd-SiglecF-PE/anti-PE, BD, Clone E50-2440/ Fluidigm, Clone PE001; 146Nd-CD8a, Fluidigm, Clone 53-6.7; 147Nd-p-H2AX[Ser139], Fluidigm, Clone JBW301; 148Nd-CD11b, Fluidigm, Clone M1/70; 149Sm-CD19, Fluidigm, Clone 6D5; 150Nd-CD25, Fluidigm, Clone3C7; 151Eu-CD64, Fluidigm, Clone X54-5/7.1; 152Sm-CD3e, Fluidigm, Clone 145-2C11; 153Eu-PD-L1, Fluidigm, Clone 10F.9G2; 154Sm-CTLA4, Fluidigm, Clone UC10-4B9; 155Gd-IRF4, Fluidigm, Clone 3E4; 156Gd-CD90.2(Thy-1.2), Fluidigm, Clone 30-H12; 158Gd-FoxP3, Fluidigm, Clone FJK-16s; 159Tb-PD-1, Fluidigm, Clone RMP1-30; 160Gd-CD80/86-FITC/anti-FITC, BD, Clone 16-10A1/BD Clone BL1/Fluidigm, Clone FIT22; 161Dy-INOS, Fluidigm, Clone 4B10; 162Dy-Tim3, Fluidigm, Clone RMT3-23; 163Dy-CXCR3-APC/anti-APCCXCR3-173, Biologend/Fluidigm, Clone APC003; 164Dy-IkBa, Fluidigm, Clone L35A5;165Ho-Beta-catenin (active), Fluidigm, Clone D13A1; 166Er-Arg1, Fluidigm, Clone 6D5; 167Er-NKp46, 2 Fluidigm, Clone 9A1.4; 168Er-Ki-67; Fluidigm, Clone Ki-67; 169Tm-Ly-6A/E (Sca-1), Fluidigm, Clone D7; 170Er-CD103-Biotin/anti-Biotin, Biolegend, Clone 2E7/Fluidigm, Clone 1D4-C5; 171Yb-CD44, Fluidigm, Clone IM7; 172Yb-CD4, Fluidigm, Clone RM4-5; 173Yb-CD117 (ckit), Fluidigm, Clone 2B8; 174Yb-Lag3, Fluidigm, Clone M5/114.15.2;175Lu-CD127, Fluidigm, Clone A7R34; 176Yb-ICOS, Fluidigm, Clone 7E.17G9; 191Ir, 193Ir-Intercalator, Cell-ID; 195Pt Cisplatin 5 uM, Cell-ID; 140Ce, 151Eu, 153 Eu, 165Ho, 175Lu Normalization Beads; Cell ID 20-Plex Pd Barcoding Kit, Fluidigm,#201060 (102, 104, 105, 106, 108, 110 Pd Bar Codes); Benzonase, Sigma #E1014-5KU(1:10,000) in HBSS.
Article Title: Adaptive immunity is required for durable responses to alectinib in murine models of EML4-ALK lung cancer
Article Snippet: Primary surface antibodies used : 89Y-CD45 (Clone 30-F11; Fluidigm), 141Pr-Gr1 (Ly6C/Ly6G; Clone RB6-8C5; Fluidigm); 142Nd-CD11c (Clone N418; Fluidigm), 143Nd-GITR (Clone DTA1; Fluidigm), 144Nd-MHCI (Clone 28-14-8; Fluidigm), SiglecF-PE (Clone E50-2440; BF), 146Nd-CD8a (Clone 53-6.7; Fluidigm), 148Nd-CD11b (Clone M1/70; Fluidigm), 149Sm-CD19 (Clone 6D5; Fluidigm), 150Nd-CD25 (Clone3C7; Fluidigm), 151Eu-CD64 (Clone X54-5/7.1; Fluidigm), 152Sm-CD3e (Clone 145-2C11; Fluidigm), 153Eu-PD-L1 (Clone 10F.9G2; Fluidigm), 154Sm-CTLA4 (Clone UC10-4B9; Fluidigm), 156Gd-CD90.2 (Clone 30-H12; Fluidigm), 159Tb-PD-1 (Clone RMP1-30; Fluidigm), 162Dy-Tim3 (Clone RMT3-23; Fluidigm), CXCR3-APC (Clone CXCR3-173; BioLegend), 167Er-NKp46 (Clone 9A1.4; Fluidigm), 169Tm-Ly-6A/E (Sca-1; Clone D7; Fluidigm), CD103-Biotin (Clone 2E7; BioLegend), 171Yb-CD44 (Clone IM7; Fluidigm), 172Yb-CD4 (Clone RM4-5; Fluidigm), 173Yb-CD117 (c-kit; Clone 2B8; Fluidigm), 174Yb-Lag3 (Clone M5/114.15.2; Fluidigm), 175Lu-CD127 (Clone A7R34; Fluidigm), 176Yb-ICOS (Clone 7E.17G9; Fluidigm), 209Bi-MHCII (I-A/I-E; Clone M5/114/15/2; Fluidigm).
Article Title: Tumor-intrinsic response to IFNγ shapes the tumor microenvironment and anti–PD-1 response in NSCLC
Article Snippet: Antibodies and reagents used were as follows: 89Y-CD45, Fluidigm, Clone 30-F11; 141Pr-Gr1 (Ly6C/Ly6G), Fluidigm, Clone RB6-8C5; 142Nd-CD11c, Fluidigm, Clone N418; 143Nd-GITR, Fluidigm, Clone DTA1; 144Nd-MHC class I, Fluidigm, Clone 28-14-8; 145Nd-SiglecF-PE/anti-PE, BD, Clone E50-2440/Fluidigm, Clone PE001; 146Nd-CD8a, Fluidigm, Clone 53-6.7; 147Nd-p-H2AX[Ser139], Fluidigm, Clone JBW301; 148Nd-CD11b, Fluidigm, Clone M1/70; 149Sm-CD19, Fluidigm, Clone 6D5; 150Nd-CD25, Fluidigm, Clone3C7; 151Eu-CD64, Fluidigm, Clone X54-5/7.1; 152Sm-CD3e, Fluidigm, Clone 145-2C11; 153Eu-PD-L1, Fluidigm, Clone 10F.9G2; 154Sm-CTLA4, Fluidigm, Clone UC10-4B9; 155Gd-IRF4, Fluidigm, Clone 3E4; 156Gd-CD90.2(Thy-1.2), Fluidigm, Clone 30-H12; 158Gd-FoxP3, Fluidigm, Clone FJK-16s; 159Tb-PD-1, Fluidigm, Clone RMP1-30; 160Gd-CD80/86-FITC/anti-FITC, BD, Clone 16-10A1/BD Clone BL1/Fluidigm, Clone FIT22; 161Dy-INOS, Fluidigm, Clone 4B10; 162Dy-Tim3, Fluidigm, Clone RMT3-23; 163Dy-CXCR3-APC/anti-APC, BioLegend, Clone CXCR3-173/Fluidigm, Clone APC003; 164Dy-IkBa, Fluidigm, Clone L35A5;165Ho-Beta-catenin (active), Fluidigm, Clone D13A1; 166Er-Arg1, Fluidigm, Clone 6D5; 167Er-NKp46, Fluidigm, Clone 9A1.4; 168Er-Ki-67; Fluidigm, Clone Ki-67; 169Tm-Ly-6A/E (Sca-1), Fluidigm, Clone D7; 170Er-CD103-Biotin/anti-Biotin, BioLegend, Clone 2E7/Fluidigm, Clone 1D4-C5; 171Yb-CD44, Fluidigm, Clone IM7; 172Yb-CD4, Fluidigm, Clone RM4-5; 173Yb-CD117 (ckit), Fluidigm, Clone 2B8; 174Yb-Lag3, Fluidigm, Clone M5/114.15.2;175Lu-CD127, Fluidigm, Clone A7R34; 176Yb-ICOS, Fluidigm, Clone 7E.17G9; 191Ir, 193Ir-Intercalator, Cell-ID; 195Pt Cisplatin 5 μM, Cell-ID; 140Ce, 151Eu, 153Eu, 165Ho, 175Lu Normalization Beads; Cell ID 20-Plex Pd Barcoding Kit, Fluidigm, #201060 (102, 104, 105, 106, 108, and 110 Pd bar codes); and Benzonase, Sigma-Aldrich #E1014-5KU (1:10,000) in HBSS.
|
fluidigm is a verified supplier 
fluidigm manufactures this product 
